Acumen Pharmaceuticals Inc. (ABOS): Price-to-Sales Ratio

Corporate company logo of Acumen Pharma (ABOS)

The price/sales multiple reflects the market valuation dynamics of Acumen Pharmaceuticals (ABOS), where is the current value of the metric. Acumen Pharmaceuticals is executing a scaling plan for its targeted antibody, confirming its efficacy. Successes in phase II trials and the probability of acquisition by industry behemoths are driving the stock's growth. The success of the therapy will ensure exceptional pricing power due to the colossal demand for Alzheimer's treatment.

ABOS: Acumen Pharmaceuticals P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Acumen Pharma (ABOS)

- share price and consensus valuation forecast:
Price Performance Chart acumenpharm.com|ABOS - Price Target Chart
- stock exchange capitalization data:
Market Valuation Acumen Pharma|ABOS - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Acumen Pharmaceuticals|ABOS - Book Capitalization|Market Capitalization to Book Value Ratio acumenpharm.com|ABOS - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Acumen Pharmaceuticals|ABOS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Acumen Pharmaceuticals, Inc|ABOS - Company Aggregate Debts|Debts to Book Capitalization Acumen Pharma|ABOS - Company Long-Term Debts|Company Current Liabilities Acumen Pharmaceuticals|Immediate Liquidity acumenpharm.com
- earnings and valuation multiples information:
ABOS - Net Income|Projected Future Earnings Acumen Pharmaceuticals|ABOS - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Acumen Pharmaceuticals Inc.|ABOS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Acumen Pharma|ABOS - Operating profit EBITDA|Net earnings per share for the last 12 months Acumen Pharmaceuticals|ABOS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth acumenpharm.com|ABOS - Earnings per share growth in current year|Net earnings per share growth forecast for next year Acumen Pharmaceuticals
- issuer revenue and sales details:
ABOS - Company Revenue|Company Future Sales acumenpharm.com|ABOS - P/S Multiple|Forward P/S Multiple Acumen Pharma
General company analysis:ABOS acumenpharm.com
Finished products of Acumen Pharmaceuticals

The intellectual capital of neurobiologists and the expansion of the clinical expert staff form the primary foundation of Acumen Pharmaceuticals (ABOS) value. The dynamics of these resources are reflected in the price-to-sales ratio, which captures market expectations. This metric compares market capitalization with sales volume, revealing the imbalance between asset valuation and actual revenue. A decline in the indicator may signal undervaluation, whereas a sharp spike warns of an overheated valuation.

Competing companies

BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC (Regencell Bioscience Ltd) - Price-to-Sales Ratio|Axsome Therapeutics Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|vikingtherapeutics.com (VKTX) - P/S Multiple|Price-to-Revenue Ratio Supernus|CPRX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Market Cap to Revenue Harmony Corp HRMY|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|Trevi Therapeutics, Inc. - P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Market Cap to Revenue|AVXL: P/S Multiple|Price to Sales CeriBell EEG (CBLL)|Market Cap to Revenue PRTA|P/S Multiple Alector Therapeutics|Market Cap to Revenue ANNX (Annexon)|Market Cap to Sales Volume OMER|P/S Multiple NGNE (Neurogene Corp)|Price-to-Revenue Coefficient AC Immune Inc (ACIU)|Voyager Therapeutics - P/S Multiple|neumoratx.com (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|Tevogen Bio Holdings Inc. (TVGN) - P/S Multiple|Price-to-Revenue Ratio Alpha Cognition Inc|Price-to-Revenue Ratio CGTX|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|Price-to-Revenue Coefficient cassavasciences.com|P/S Multiple ASRT (Assertio)|P/S Multiple Coya Therapeutics Inc COYA|VistaGen Therapeutics Inc - P/S Multiple|OVID: Price-to-Revenue Ratio|CervoMed Inc. (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Limited (ATHE)|Price-to-Revenue Ratio Clene Inc|PepGen Corp (PEPG) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|Relmada Corp - Market Cap to Revenue Ratio|P/S Multiple ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Price to Sales|AIFF: Market Cap to Revenue|KLTO - P/S Multiple|neurosense-tx.com (NRSN) - Price-to-Revenue Ratio|Reviva Pharmaceuticals, Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio MetaVia Inc.|Price to Sales neuraxis.com NRXS|P/S Multiple HSDT|P/S Multiple passagebio.com (PASG)|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV - Market Cap to Revenue|ATHA: Market Cap to Revenue|ADXN - P/S Multiple|alzamend.com (ALZN) - Price-to-Revenue Ratio|Market Cap to Revenue Cyclerion Therapeutics, Inc.|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Price to Sales Pasithea KTTA|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|avenuetx.com - Market Cap to Revenue Ratio|BrainStorm Cell Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CARA|CHRO - Price-to-Revenue Ratio|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|longboardpharma.com - Market Capitalization-to-Revenue Ratio|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|P/S Multiple NKGen Biotech Inc|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|TRVN - Market Cap to Revenue|Vigil Neuro - P/S Multiple|WENA - P/S Multiple|CERE: P/S Multiple